# METANOVA (NCT06150417)

> MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: de novo oligometastatic prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06150417
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Case Comprehensive Cancer Center
- Conditions: Prostate Cancer; Malignant Neoplasm of Prostate; Secondary Malignant Neoplasm of Prostate
- Interventions: Androgen deprivation therapy (ADT); Androgen receptor signaling inhibitor (ARSI); Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT); Metastasis directed radiotherapy (MDRT)
- Enrollment: 200
- Primary outcome: Failure-free survival (FFS)

## Indexed commentary on METANOVA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 10 posts on X
- 2 YouTube videos
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=metanova-nct06150417

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06150417", "email": "<work email>"}; the inbox owner confirms by the emailed link.